Shengnuo Pharmaceuticals-B(02257) issued an announcement50freespinsnodeposit, Dai Xiaochang resigned as the group's chief strategy officer due to personal reasons50freespinsnodeposit, effective from May 17, 2024. Dr. Dai will continue to serve as executive director and agreed to serve as senior consultant for the group's drug development and commercialization.
